R. O'Neil Patrick's most recent trade in Ionis Pharmaceuticals Inc was a trade of 20,000 Common Stock done at an average price of $60.9 . Disclosure was reported to the exchange on Sept. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.89 per share. | 09 Sep 2025 | 20,000 | 77,130 (0%) | 0% | 60.9 | 1,217,800 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 20,000 | 34,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 64.56 per share. | 09 Sep 2025 | 20,000 | 57,130 (0%) | 0% | 64.6 | 1,291,106 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 1,000 | 57,203 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 64.56 per share. | 09 Sep 2025 | 1,000 | 57,130 (0%) | 0% | 64.6 | 64,555 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.78 per share. | 09 Sep 2025 | 1,000 | 58,130 (0%) | 0% | 56.8 | 56,780 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 60.89 per share. | 02 Sep 2025 | 65,475 | 5,655 (0%) | 0% | 60.9 | 3,986,773 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 49,800 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.77 per share. | 02 Sep 2025 | 49,800 | 57,130 (0%) | 0% | 53.8 | 2,677,746 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 14,000 | 8,942 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.58 per share. | 02 Sep 2025 | 14,000 | 71,130 (0%) | 0% | 37.6 | 526,120 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 13,050 | 4,467 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 13,050 | 17,517 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.60 per share. | 02 Sep 2025 | 13,050 | 18,705 (0%) | 0% | 32.6 | 425,430 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 54.51 per share. | 02 Sep 2025 | 13,050 | 57,130 (0%) | 0% | 54.5 | 711,418 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.60 per share. | 02 Sep 2025 | 13,050 | 70,180 (0%) | 0% | 32.6 | 425,430 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 61.42 per share. | 02 Sep 2025 | 11,375 | 7,330 (0%) | 0% | 61.4 | 698,653 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Other type of transaction at price $ 27.71 per share. | 29 Aug 2025 | 331 | 57,130 (0%) | 0% | 27.7 | 9,172 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Other type of transaction at price $ 28.21 per share. | 28 Feb 2025 | 554 | 56,799 (0%) | 0% | 28.2 | 15,629 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 32.35 per share. | 20 Feb 2025 | 1,207 | 56,245 (0%) | 0% | 32.3 | 39,046 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 31.62 per share. | 04 Feb 2025 | 6,165 | 57,452 (0%) | 0% | 31.6 | 194,939 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 3,820 | 65,023 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 32.49 per share. | 30 Jan 2025 | 1,406 | 63,617 (0%) | 0% | 32.5 | 45,685 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 33,000 | 80,414 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 22,000 | 64,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 19,690 | 68,563 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 19,690 | 60,724 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 32.83 per share. | 15 Jan 2025 | 7,360 | 61,203 (0%) | 0% | 32.8 | 241,629 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 22,000 | 22,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Other type of transaction at price $ 38.64 per share. | 30 Aug 2024 | 246 | 48,873 (0%) | 0% | 38.6 | 9,506 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 49.67 per share. | 02 Feb 2024 | 1,995 | 48,627 (0%) | 0% | 49.7 | 99,099 | Common Stock |
| Ionis Pharmaceuticals Inc | O'Neil R. Patrick | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 3,820 | 50,622 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | R. Patrick O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 49.67 per share. | 01 Feb 2024 | 1,961 | 48,661 (0%) | 0% | 49.7 | 97,410 | Common Stock |
| Ionis Pharmaceuticals Inc | R. O'Neil Patrick | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 51.75 per share. | 25 Jan 2024 | 6,450 | 46,802 (0%) | 0% | 51.8 | 333,788 | Common Stock |
| Ionis Pharmaceuticals Inc | R. Patrick O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 20,641 | 47,414 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Patrick O'Neil R. | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 20,641 | 60,996 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | R. O'Neil Patrick | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 50.42 per share. | 16 Jan 2024 | 7,744 | 53,252 (0%) | 0% | 50.4 | 390,429 | Common Stock |
| Ionis Pharmaceuticals Inc | O'Neil R. Patrick | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 20,400 | 68,055 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | R. Patrick O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 17,000 | 42,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Patrick O'Neil R. | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 27,200 | 27,200 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick O'Neil R. | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 26 Dec 2023 | 20,825 | 61,180 (0%) | 0% | 47.3 | 985,856 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 51.46 per share. | 26 Dec 2023 | 20,825 | 40,355 (0%) | 0% | 51.5 | 1,071,717 | Common Stock |
| Ionis Pharmaceuticals Inc | R. O'Neil Patrick | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2023 | 20,825 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 41.70 per share. | 24 May 2023 | 1,527 | 40,355 (0%) | 0% | 41.7 | 63,676 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Other type of transaction at price $ 30.51 per share. | 28 Feb 2023 | 301 | 41,882 (0%) | 0% | 30.5 | 9,185 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 3,822 | 43,501 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 40.86 per share. | 03 Feb 2023 | 1,920 | 41,581 (0%) | 0% | 40.9 | 78,460 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 39.71 per share. | 30 Jan 2023 | 4,500 | 39,679 (0%) | 0% | 39.7 | 178,700 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 39.42 per share. | 30 Jan 2023 | 4,500 | 44,179 (0%) | 0% | 39.4 | 177,372 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 21,871 | 47,655 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 21,871 | 56,515 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 39.49 per share. | 17 Jan 2023 | 7,836 | 48,679 (0%) | 0% | 39.5 | 309,480 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 17,207 | 69,526 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 14,338 | 25,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,942 | 22,942 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Other type of transaction at price $ 28.97 per share. | 31 Aug 2022 | 108 | 34,644 (0%) | 0% | 29.0 | 3,129 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 40.06 per share. | 12 Apr 2022 | 6,792 | 34,536 (0%) | 0% | 40.1 | 272,057 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Other type of transaction at price $ 28.37 per share. | 28 Feb 2022 | 735 | 41,328 (0%) | 0% | 28.4 | 20,854 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 21,086 | 52,319 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 21,086 | 48,094 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.12 per share. | 18 Jan 2022 | 7,501 | 40,593 (0%) | 0% | 30.1 | 225,930 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 15,284 | 73,405 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 11,463 | 11,463 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 30,567 | 30,567 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP Legal & General Counsel | Other type of transaction at price $ 33.80 per share. | 31 Aug 2021 | 309 | 27,008 (0%) | 0% | 33.8 | 10,443 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP & General Counsel | Other type of transaction at price $ 44.54 per share. | 26 Feb 2021 | 197 | 26,699 (0%) | 0% | 44.5 | 8,774 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 63.50 per share. | 25 Jan 2021 | 5,324 | 26,502 (0%) | 0% | 63.5 | 338,074 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 25,868 | 25,868 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 16,504 | 37,682 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 16,504 | 32,253 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.28 per share. | 15 Jan 2021 | 5,856 | 31,826 (0%) | 0% | 61.3 | 358,856 | Common Stock |
| Ionis Pharmaceuticals Inc | Patrick R. O'Neil | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 58,203 | 58,203 | - | - | Employee Stock Option (right to buy) |